SA technical overview of the FM-AHA-A102 auto hematology analyzer — covering the Coulter impedance principle, 21-parameter CBC reporting, reagent system, laboratory applications, and practical guidance for instrument selection in diagnostic and research settings.
Complete blood count (CBC) testing is among the most frequently ordered laboratory procedures in clinical medicine. It provides quantitative data on red blood cell mass, white blood cell count and differential, and platelet concentration — parameters that collectively inform the diagnosis of anaemia, infection, haematological malignancy, coagulation disorders, and systemic inflammatory conditions. The accuracy and reproducibility of CBC results depend directly on the measurement principles and instrument configuration of the hematology analyzer producing them.
The FM-AHA-A102 is a 3-part differential automatic hematology analyzer from Fison that operates on the electrical impedance method — the foundational measurement principle on which most clinical hematology platforms are based. This article examines how that principle is implemented in the FM-AHA-A102, what its 21-parameter output covers, how reagents interact with sample processing, and what distinguishes a 3-part from a 5-part differential system in clinical practice.
Fig. 1 — FM-AHA-A102 CBC parameter distribution across the WBC, RBC, and PLT cell lines (21 total reportable parameters)
The automated hematology analyzer principle implemented in the FM-AHA-A102 is based on electrical impedance detection — a method developed by Wallace Coulter in the 1950s and subsequently adopted as the reference technology for particle counting in clinical hematology. The principle operates as follows: a diluted blood sample is drawn through a small aperture across which an electrical current is maintained. When a blood cell passes through the aperture, it displaces a volume of electrolyte solution proportional to the cell's size, momentarily increasing the electrical resistance and producing a measurable voltage pulse.
The amplitude of each voltage pulse corresponds to the cell volume (size), and the total count of pulses per unit volume gives the cell concentration. This allows the FM-AHA-A102 to simultaneously count and size cells across three separate measurement channels: the WBC aperture, the RBC/PLT aperture, and the haemoglobin photometric channel.
Fig. 2 — Coulter impedance principle: voltage pulses generated as cells pass through the aperture are counted and sized by the microprocessor to produce CBC parameters and histograms
Haemoglobin concentration is measured independently by a photometric method: the sample is lysed and converted to a stable chromogen, and absorbance at a specific wavelength is used to calculate HGB concentration. This two-technology approach — impedance for cell counting and photometry for HGB — is the standard architecture of the 3-part differential auto hematology analyzer category. Derived parameters such as MCV, MCH, MCHC, RDW, MPV, and PCT are calculated mathematically from the primary measurements rather than directly measured, which is an important distinction when evaluating inter-analyser result comparability.
Consistent auto hematology analyzer reagent quality is a prerequisite for analytical performance. The FM-AHA-A102 uses three primary reagent types, each performing a distinct biochemical role in the measurement cycle.
An isotonic electrolyte solution that dilutes the whole blood sample to a concentration suitable for aperture counting. The diluent must maintain the osmolarity required to preserve cell morphology and size during measurement, as osmotic stress will alter RBC volume and produce falsely shifted MCV readings. Diluent quality directly affects the accuracy of all impedance-derived parameters.
The lyse reagent selectively disrupts red blood cell membranes, releasing haemoglobin into solution for photometric measurement and lysing RBCs so that white blood cells remain countable. In the WBC channel, the lyse reagent produces partial membrane disruption of leukocytes to create the size-based size differences that the impedance method uses to separate lymphocytes from mid-range cells and granulocytes in the 3-part differential output.
A surfactant-based cleaning solution flushed through the fluidic pathway between samples. This removes biological residue from the aperture, tubing, and mixing chambers. The FM-AHA-A102's automatic fault handling and cleaning function automates this process, reducing carryover risk between samples and maintaining aperture integrity over extended daily operation.
The WBC differential is the component of the CBC most directly tied to clinical interpretation of infection, immune status, and haematological disease. Understanding the capabilities and limitations of the 3-part differential relative to the 5-part configuration is essential for matching the analyzer to the laboratory's clinical purpose.
Separates WBCs into three populations: lymphocytes, mid-range cells (monocytes, eosinophils, basophils grouped together), and granulocytes (primarily neutrophils). Separation is achieved entirely by cell size after lyse treatment using impedance. This configuration is appropriate for routine CBC screening, where the primary question is whether the WBC count is elevated or depressed and whether the differential pattern suggests predominantly lymphocytic or granulocytic change. Flags are generated for populations that fall outside expected size distributions, prompting manual microscopy review.
Separates WBCs into five populations: neutrophils, lymphocytes, monocytes, eosinophils, and basophils individually. Typically uses dual-channel detection combining impedance with light scatter or optical fluorescence. Provides specific eosinophil and basophil counts that the 3-part system groups into the mid-range population. Required for patients with suspected eosinophilic disorders, haematological malignancy, or where individual monocyte quantification is clinically indicated.
| Feature | FM-AHA-A102 (3-Part) | FM-AHA-A103 (5-Part) |
|---|---|---|
| WBC Differential Populations | 3 (LYM / MID / GRA) | 5 (NEU / LYM / MON / EOS / BAS) |
| Reportable Parameters | 21 | 25 |
| Detection Method | Electrical impedance | Impedance + optical scatter |
| Individual Eosinophil Count | ||
| Scattergram Output | ||
| Throughput | 60 tests/hr | Varies by model |
| Suitable for Routine CBC Screening | ||
| Haematological Malignancy Workup | Flag for review |
The FM-AHA-A102 is positioned within the auto hematology analyzer category for moderate-to-high volume clinical environments where rapid CBC throughput and structured data reporting are operational priorities.
Processes inpatient and emergency department CBC requests with 60-test-per-hour throughput. The built-in thermal printer supports immediate report generation at the instrument without requiring a networked laboratory information system for basic reporting workflows.
Supports outpatient CBC panels and health screening programs where specimen volume is moderate and 3-part differential resolution is sufficient for the clinical questions being addressed. Results flag abnormal populations for manual morphology review, maintaining a quality-gated reporting pathway.
Pre-donation donor screening requires rapid CBC and haemoglobin assessment. The FM-AHA-A102's 10 µL minimum sample volume and 60-test-per-hour throughput accommodate the workflow demands of busy donation session scheduling without processing delays.
Animal and human study protocols requiring serial CBC measurements benefit from the FM-AHA-A102's 10 µL sample volume, which is compatible with the small blood volumes available from rodent and small animal models. The 21-parameter output provides comprehensive haematological phenotyping across study cohorts.
Neonatal and paediatric blood sampling is constrained by available volume. The capillary and pre-diluted sample modes of the FM-AHA-A102 allow CBC testing from fingertip or heelprick specimens, making the instrument appropriate for settings where venepuncture volumes are clinically limited.
Clinical trials requiring haematological safety monitoring produce regular CBC data points per participant. The FM-AHA-A102's structured 21-parameter output and data export capability support the regulatory-grade data management requirements of GCP-compliant trial laboratory operations.
The FM-AHA-A102 generates three histograms as part of each CBC report: the WBC size distribution histogram, the RBC volume distribution histogram, and the platelet volume distribution histogram. Each histogram plots cell count against cell volume across the measured size range, providing a graphical representation of population distribution that complements the numerical parameter output.
Fig. 3 — Illustrative histogram profiles for WBC (3-part differential), RBC volume distribution, and PLT volume distribution generated by the FM-AHA-A102
The WBC histogram is particularly relevant for clinical interpretation: the three distinct population zones should separate clearly in a normal sample, with the LYM peak in the low-volume region, a flat MID zone, and the GRA peak in the high-volume region. Abnormal patterns — such as a raised MID zone, a bimodal LYM peak, or an absent GRA peak — are flagged by the instrument and indicate specimens requiring manual blood film examination for morphological characterisation.
The RBC histogram provides direct visual assessment of anisocytosis (RBC volume variation), which correlates numerically with the RDW-CV and RDW-SD parameters. A broad, flattened RBC histogram peak indicates high red cell size variability, a pattern associated with mixed nutritional deficiency anaemia and post-transfusion samples. The PLT histogram characterises platelet volume distribution, supporting the clinical utility of the MPV and PDW indices in assessing platelet activation status.
| Parameter | Specification | Standard / Compliance |
|---|---|---|
| Analyzer Type | 3-part differential, fully automated | ISO 15189 |
| Reportable Parameters | 21 CBC parameters | ISO 15189 |
| Histograms | 3 (WBC, RBC, PLT) | ASTM E1498 |
| Throughput | 60 tests per hour | ISO 9001 |
| Sample Volume | 10 µL whole blood | IEC 61010-2-101 |
| Measurement Principle | Electrical impedance (Coulter method) + photometry (HGB) | ASTM E2517 |
| Display | 10.4-inch colour LCD touchscreen | IEC 61010-1 |
| Printer | Built-in thermal; external laser/inkjet supported | ISO 9001 |
| Sample Modes | Whole blood, capillary blood, pre-diluted | ISO 15189 |
| Maintenance | Automatic fault handling and cleaning function | EN ISO 17511 |
| Certification | CE marked | CEEN 61010-1 |
| Applications | Hospitals, diagnostic labs, research centres, blood donation centres | ISO 15189 |
Procurement decisions for hematology analyzers frequently involve trade-offs that are not always visible in specification sheets. The following are the most commonly encountered selection errors in clinical and research laboratory settings.
If the laboratory's primary requirement is routine CBC screening — pre-operative panels, general health checks, and monitoring of chronic conditions — a 3-part differential system provides the necessary clinical data at lower reagent consumption and instrument complexity. Specifying a 5-part platform for a predominantly screening workflow increases operating overhead without proportional diagnostic gain.
Laboratories serving paediatric, neonatal, or oncology patient populations frequently encounter blood volume constraints. An instrument requiring 100–200 µL per test cannot accommodate fingerprick capillary specimens or the limited phlebotomy volumes practicable in neonates. Verifying minimum sample volume requirements against the patient population is a prerequisite step in analyzer selection, not an afterthought.
Hematology analyzers are designed around specific reagent formulations optimised for their aperture dimensions and lyse chemistry. Using non-validated reagents from alternative suppliers modifies the lyse-to-cell ratio and can shift WBC differential boundaries, producing systematically incorrect population percentages. Reagent-analyser compatibility validation should be part of the instrument qualification process, not an ad-hoc cost-reduction measure.
A high flag rate from an automated hematology analyzer increases the volume of samples requiring manual blood film review, which negates some of the throughput advantage of automation. Evaluating the flag rate performance of an instrument using the laboratory's actual specimen mix during a pre-purchase validation is the only way to accurately project the downstream manual review workload the instrument will generate.
Browse the complete auto hematology analyzer series and related laboratory instruments from Fison
Auto hematology analyzer models from Fison:
Access the complete technical datasheet, parameter list, and model comparison for the Fison FM-AHA-A102 auto hematology analyzer on the product page.
View FM-AHA-A102 Product PageContact Us